Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b623f88272f979483d05296c1f30b899 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_29d5f51c5d11671c9918f7dc55913593 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0026 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6921 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6923 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0026 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48215 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-48861 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69 |
filingDate |
2018-05-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b0f1027aa68aa4819148c89c7ff6e4c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33229718ca0efab0d2b37514abe88ae4 |
publicationDate |
2018-09-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2018264035-A1 |
titleOfInvention |
Reducing the proliferation of adenocarcinoma cells (caco-2) by administration of a poly-oxygenated metal hydroxide |
abstract |
A method of treating a mammal, comprising administering a therapeutically effective amount of a poly-oxygenated metal hydroxide composition to a mammal to reduce a proliferation of hypoxic carcinoma cells, wherein the poly-oxygenated metal hydroxide composition comprises a clathrate containing free oxygen gas (O 2 ) molecules. The carcinoma cells may comprise colon adenocarcinoma cells (CaCo-2). The poly-oxygenated metal hydroxide material is configured to provide bioavailable oxygen gas molecules to a mammal when administered to the mammal. The poly-oxygenated metal hydroxide composition can be administered intravenously, directly to carcinoma cells, and orally. The composition may comprise a fluid, where the poly-oxygenated metal hydroxide composition is soluble in the fluid. |
priorityDate |
2016-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |